The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke

Tsai, Nai‐Wen; Lin, Tsu-Kung; Chen, Shang-Der; Chang, Wen-Neng; Wang, Hung-Chen; Yang, Tsung Han; Lin, Yujun; Jan, Chung‐Ren; Huang, Chi-Ren; Liou, Chia‐Wei; Lu, Cheng-Hsien

doi:10.1016/j.cca.2010.11.036

Cited by 141 publications

(113 citation statements)

References 31 publications

Supporting

Mentioning

102

Contrasting

Unclassified

Order By: Relevance

“…Elevated levels of circulating mtDNA in the setting of trauma and neurological injury have been associated with poor clinical outcomes (19,29,(56)(57)(58)(59)(60). While there is accumulating evidence that circulating mtDNA is associated with systemic inflammation, it has not been previously examined whether mtDNA is circulating as free DNA complexed within subcellular particles, or as free extracellular mitochondria.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction

et al. 2018

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

“…of patients following trauma (25,26), in patients with myocardial (27,28) and neurologic tissue injury (29,30), and in setting of sepsis (31,32). However, the role of mitochondria-derived DAMPs (mtDAMPs) has not been investigated in the setting of brain death, nor has their effect on allograft function been described.…”

Section: Introductionmentioning

confidence: 99%

Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction

et al. 2018

View full text Add to dashboard Cite

“…First discovered in 1948 by Mandel and Metais, fragmented DNA or cfDNA has since been associated with a number of conditions, including end-stage renal disease, myocardial infarction, stroke, and trauma [2][3][4][5][6][7]. Multiple studies have shown a correlation between the levels of cfDNA and cellular injury and necrosis, processes relevant in cancer cell survival and propagation.…”

Section: Cfdnamentioning

confidence: 99%

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

Levy

Cordova

et al. 2016

The Oncologist

View full text Add to dashboard Cite

A firmer understanding of the genomic landscape of lung cancer has recently led to targeted, therapeutic advances in non-small cell lung cancer. Historically, the reference standard for the diagnosis and genetic interrogation for advanced-stage patients has been tissue acquisition via computed tomography-guided core or fine needle aspiration biopsy. However, this process can frequently put the patient at risk and remains complicated by sample availability and tumor heterogeneity. In addition, the time required to complete the diagnostic assays can negatively affect clinical care. Technological advances in recent years have led to the development of blood-based diagnostics or “liquid biopsies” with great potential to quickly diagnose and genotype lung cancer using a minimally invasive technique. Recent studies have suggested that molecular alterations identified in cell-free DNA (cfDNA) or circulating tumor DNA can serve as an accurate molecular proxy of tumor biology and reliably predict the response to tyrosine kinase therapy. In addition, several trials have demonstrated the high accuracy of microRNA (miRNA) platforms in discerning cancerous versus benign nodules in high-risk, screened patients. Despite the promise of these platforms, issues remain, including varying sensitivities and specificities between competing platforms and a lack of standardization of techniques and downstream processing. In the present report, the clinical applications of liquid biopsy technologies, including circulating tumor cells, proteomics, miRNA, and cfDNA for NSCLC, are reviewed and insight is provided into the diagnostic and therapeutic implications and challenges of these platforms.

show abstract

“…Levels of plasma nuclear cfDNA were 5,575 kGE L À1 in the poor and 5,120 kGE L À1 in the good outcome group, whereas levels of plasma mitochondrial cfDNA were 3,121 kGE L À1 in the poor and 2,333 kGE L À1 in the good outcome group. This study indicates that in acute stage patients the levels of cfDNA reflects the clinical severity of ischemic stroke and may be useful for risk stratification [22]. A further study, showing the correlation between plasma cfDNA concentrations and the volume of cerebral hematoma, quantified the levels of cellfree β-globin in 70 patients with ischemic stroke, 11 patients with intracerebral hemorrhage and seven patients with transient ischemic attacks.…”

Section: Strokementioning

confidence: 91%

CNAPS and General Medicine

Schwarzenbach

2014

Advances in Predictive, Preventive and Personalised Medicine

View full text Add to dashboard Cite

The identification of blood-based markers that help clinicians to diagnose, predict and monitor diseases is a great challenge. In general, the earlier a precise diagnosis and therapy can be applied, the higher the probability of a successful treatment of the patients. Cell-free nucleic acids have promising clinical potential because they can critically be dysregulated during pathogenic processes. They are usually released during cellular stress or tissue injury and related to inflammatory responses caused by a coordinated expression of numerous genes that initiate, sustain and propagate immune responses and tissue remodeling. Although there is a potential for the application of cell-free nucleic acids as clinical assays, their use as potential biomarkers in pathologic conditions is still at the experimental stage, partly due to different qualities of the analyses employed. With the exception of minimally invasive prenatal diagnostic tests, the approaches on circulating, cell-free DNA, mRNA and microRNAs applicable for clinical practice currently remain somewhat elusive.

show abstract

The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke

Cited by 141 publications

References 31 publications

Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction

Circulating mitochondria in deceased organ donors are associated with immune activation and early allograft dysfunction

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer

CNAPS and General Medicine

Contact Info

Product

Resources

About